MedTrace Logo

Laryngeal Nerve Block for Chronic Cough

NCT05292677 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-23

No results posted yet for this study

Summary

The purpose of this study is to study the potential benefit of treating chronic neurogenic cough by blocking the nerve responsible for the disease with an injection of local anesthetic/steroid mixture versus a placebo.

Conditions

  • Laryngeal Nerve Block
  • Chronic Neurogenic Cough
  • Laryngeal Hypersensitivity

Interventions

DRUG

Steroid/Anesthesia Mixture

Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.

DRUG

Placebo

2 mL of Normal Saline

Sponsors & Collaborators

  • Eastern Virginia Medical School

    lead OTHER

Principal Investigators

  • Benjamin Rubinstein, MD · Eastern Virginia Medical School Department of Otolaryngology - Head and Neck Surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-21
Primary Completion
2023-06-25
Completion
2023-06-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05292677 on ClinicalTrials.gov